IgG serology in health care and administrative staff populations from 7 hospitals representative of different exposures to SARS-CoV-2 in Lombardy, Italy

Maria Teresa Sandri[1, †] , Elena Azzolini[1, †], Valter Torri[3], Sara Carloni[1], Michele Tedeschi[1], Massimo Castoldi[5], Alberto Mantovani[1,2,4] , Maria Rescigno[1,2*]

[1]Humanitas Clinical and Research Center – IRCCS, Via Manzoni 56, 20089 Rozzano – Milan, Italy

[2]Humanitas University Department of Biomedical Sciences, Via Rita Levi Montalcini, 20090 Pieve Emanuele – Milan, Italy

[3]Istituto di Ricerche Farmacologiche "Mario Negri" - IRCCS, Via Mario Negri, 2 20156 Milano, Italy

[4]The William Harvey Research Institute, Queen Mary University of London, London EC1M 6BQ, UK.

[5]Humanitas Gavazzeni and Castelli, Via Mauro Gavazzeni 21, Bergamo, Italy

Abstract

Lombardy is one of the regions in Italy most affected by COVID-19. We assessed the diffusion of the virus via testing plasma anti-SARS-CoV-2 IgG antibodies in 3985 employees of 7 different hospitals, located across the Lombardy region in areas with different exposure to the epidemic. Subjects filled an anamnestic questionnaire to self-report on COVID-19 symptoms, co-morbidities, smoking, regular or smart-working, and the exposure to COVID-19-infected individuals. We show that the number of individuals exposed to the virus depended on the geographical area where the hospital was located and ranged between 3 to 43% which correlated with the incidence of COVID-19 in Lombardy. There was a higher prevalence of females than males positive for IgG, however the level of antibodies was similar, suggesting a comparable magnitude of the response. We observed 10% of IgG positive asymptomatic individuals and another 20% with one or two symptoms. 81% of individuals presenting both anosmia/ageusia and fever resulted SARS-CoV-2 infected. IgG positivity correlated with family contacts.

In conclusion, the frequency of IgG positivity and SARS-CoV-2 infection is dependent on the geographical exposure to the virus and to extra-hospital exposure.

Correspondence to:

Prof. Maria Rescigno, maria.rescigno@hunimed.eu

Humanitas University, Via Rita Levi Montalcini, 4; 20090 Pieve Emanuele (Mi) Italy

Abstract

Lombardy is one of the regions in Italy most affected by COVID-19. We assessed the diffusion of the virus via testing plasma anti-SARS-CoV-2 IgG antibodies in 3985 employees of 7 different hospitals, located across the Lombardy region in areas with different exposure to the epidemic. Subjects filled an anamnestic questionnaire to self-report on COVID-19 symptoms, co-morbidities, smoking, regular or smart-working, and the exposure to COVID-19-infected individuals. We show that the number of individuals exposed to the virus depended on the geographical area where the hospital was located and ranged between 3 to 43% which correlated with the incidence of COVID-19 in Lombardy. There was a higher prevalence of females than males positive for IgG, however the level of antibodies was similar, suggesting a comparable magnitude of the response. We observed 10% of IgG positive asymptomatic individuals and another 20% with one or two symptoms. 81% of individuals presenting both anosmia/ageusia and fever resulted SARS-CoV-2 infected. IgG positivity correlated with family contacts.

In conclusion, the frequency of IgG positivity and SARS-CoV-2 infection is dependent on the geographical exposure to the virus and to extra-hospital exposure.

Introduction

Lombardy has been the Italian region most affected by SARS-Cov-2 infection with more than 80,000 cases from the outbreak and a mortality rate of nearly 18% (as of May 8th, https://utils.cedsdigital.it/coronavirus/#regioni1). Only symptomatic individuals have been tested by RT-PCR to detect SARS-CoV-2, and hence the actual spreading of the virus, particularly in the asymptomatic population, is unknown. In addition, detection of viral RNA, besides not being very sensitive in cases of low viral load [1] and potentially suffering from pre-analytical pitfalls [2], it is just a photography of the exact moment of the infection. Hence unless being continuously monitored by viral testing, the asymptomatic individuals' infected state may be missed.

A retrospective way to assess viral spread is via the analysis of an immune response that can be detected through the development of immunoglobulins [3]. Indeed, almost the totality (>95%) of laboratory-confirmed COVID-19 showed seroconversion even using different methodologies and antibody isotypes (ELISA, EIA, anti-IgM, anti Ig-G or anti Ig-A) [3-7]. Interestingly, the dynamic of the immune response to SARS-CoV-2 is very peculiar and patient dependent. IgM for instance, which should be the first type of immunoglobulins to appear under normal circumstances, are detected before, concomitant or even after IgGs, or do not appear at all [3,8]. This suggests that differently from other infectious diseases, in SARS-CoV-2 infection, IgG is a more reliable marker for seroconversion than IgM.

Although on a small number of individuals, IgG analysis allowed to detect nearly 4.3% (7/164) of viral RNA negative asymptomatic relatives of COVID-19 patients [3], suggesting that anti-SARS-CoV-2 IgG may be used as a diagnostic tool to detect the incidence of asymptomatic infections even in cases of impossibility of viral detection. Based on these assumptions, we tested the presence of plasma anti- SARS-CoV-2 IgG antibodies in nearly 4000 (3985) employees of 7 different hospitals, one including a research center and a University, located across the Lombardy region in areas with different exposure to the epidemic (Milan, Rozzano, Varese, Castellanza and Bergamo (the city most affected by the pandemic per number of individuals)).

Results

Study population

Accrual was on a voluntary basis: it started on April 28th and more than 65% of employees participated as of May 16th, 2020 (clinicaltrial.gov NCT04387929). 7 different centers participated to the study: Istituto Clinico Humanitas (ICH), Rozzano, Mi; Humanitas Gavazzeni, Bergamo; Humanitas Castelli, Bergamo; Humanitas Mater Domini (HMD), Castellanza (Va); Humanitas

Medical Center, HMC, Varese, Mi; Humanitas University, Pieve Emanuele (Mi); Humanitas San Pio X, Milano. The individuals were healthcare professionals (physicians (16.5%), surgeons (7.2%) anesthesiologists (2.8%), physiotherapists (1.8%), nurses (25.4%)), laboratory technicians (4.3%), students (0.7%), researchers/academics (3.1%), administrative staff (10%), customer service (front desk, check-in) (10%) (Table 1). 66.8% were females and 33.2% males, median age 42 yo (21 -86 yo).

Subjects filled an anamnestic questionnaire reporting whether they had COVID-associated symptoms, including fever, dry cough, fatigue, soreness and muscle pain, runny nose, sore throat, gastrointestinal symptoms (including vomiting, nausea, diarrhea), pneumonia, severe acute respiratory syndrome, anosmia/hyposmia, ageusia. They also reported on body mass index (BMI), co-morbidities (hypertension, heart disease or diabetes, immunosuppression), smoking, regular or smart-working, the frequency of home exits for non-work related reasons and the exposure to COVID-infected individuals.

Frequency of IgG positivity across the population

Anti-S1 and anti-S2 SARS-CoV-2 IgG specific antibodies were detected via an indirect chemiluminescence immunoassay. According to kit manufacturer, the test discriminates among negative (<12AU/mL; with 3.8 as the limit of IgG detection), equivocal (12.0 – 15.0 AU/mL) and positive (> 15.0 AU/mL) subjects. Of 3985 enrolled subjects, 3462 (87%) were negative, 76 (2%) equivocal and 447 (11%) positive (which together with equivocal summed up to 523 (13%) (Table 1). We decided to group together equivocal and truly positive subjects as they behaved very similarly in subsequent analyses (as for instance in correlation with the number of symptoms (Suppl. Fig. 1A, B)). When we analyzed IgG positivity (>12 AU/mL) divided by sex, we found a statistically significant difference ($p=0.03$) between males (11%) and females (14%) (Table 1). There was no difference according to BMI, but cigarette smoking was associated to a reduction of IgG positivity (Table 1 and Suppl. Fig. 1C, $p<.0001$).

The number of individuals exposed to the virus reflected the geographical area where the hospital was located (Fig. 1A). Two hospitals based in Bergamo (Humanitas Gavazzeni and Castelli) were the most affected as between 35 and 43 % of the whole population was IgG positive (Fig. 1B). In the other hospitals the frequency of IgG positivity ranged between 3% (HMC) and 9% (ICH) (Fig. 1B). This difference among the 7 sites was highly statistically significant (Suppl. Table 1, $P<0.0001$). Interestingly, HMC which had the lowest incidence of IgG positive individuals (3%), is located in Varese, which is one of the less COVID-affected province in Lombardy (https://www.lombardianotizie.online/coronavirus-casi-lombardia/).

Interestingly, as shown in Table 1 and Fig. 2A, we observed a higher proportion of IgG positive individuals in females than males (*p=0.03*). This difference was consistent across the different sites (Fig. 2, Suppl. Table 1).

We then evaluated whether there was a difference in the positivity to IgG according to age. We found that there was a Gaussian distribution of the number of IgG positive (>12 AU/mL) individuals across the age range (Fig. 3A), but then when analyzing the frequency of positivity at the different age ranges we observed an age dependent reduction of IgG positive individuals (Fig. 2B). However, this age-dependency was primarily due to the female rather than the male population, particularly for subjects either young or older than 60 yo. (Fig. 3B). In older than 60 yo, IgG positivity dropped from 12% in males to 5% in females (p for heterogeneity *p=0.01*). This indicates that females are more likely to be infected – or to induce an IgG response - when young, and less likely at ages higher than 60 yo. On the contrary, middle-aged males are more likely to induce an antibody response.

All 523 subjects >12 AU/mL underwent a rinopharyngeal swab for SARS-CoV-2 RNA viral detection. Of these, only 39 (7.6%) resulted positive for viral RNA detection and there was no significant difference between equivocal and truly positive IgG individuals (Table 2). However, in 31 of these (79.5%), the subjects tested negative for at least one of the genomic sequences of the three SARS-CoV-2 gene targets: *E, RdRp* and *N*. To rule out that the negative population (IgG 3.8-12 AU/mL) comprised individuals in the early phases of viral infection, a sample of 46 individuals underwent a rinopharyngeal swab for SARS-CoV-2 RNA viral detection. All of them resulted negative to the swab confirming the negativity of the test below 12 AU/mL (Table 2).

We then evaluated the proportion of IgG positive individuals (IgG > 12 AU/mL) across the different professional status and found that employees dealing with patients such as healthcare professionals (both physicians and nurses) had a higher percentage of IgG positive individuals, while employees in research and customer care were less frequently IgG positive. Interestingly, hospital administrative staff had a similar percentage of positivity as healthcare professional (Table 1 and Fig. 3C), even though many worked from home. This was true also when analyzing the centers differently exposed to the virus: Gavazzeni with Castelli versus ICH (Suppl. Fig. 2A), suggesting a geographical rather than a hospital exposure. We were quite surprised to see such a difference between research personnel and staff personnel in terms of frequency of IgG positive individuals as many of the research staff continued working also during lockdown. This was not related to an age difference because, if something, we would have expected the opposite as the age of the research personnel was significantly lower than that of the staff (Suppl. Fig. 2B) and there was a similar proportion of females versus males (Suppl. Fig. 2C). We hypothesized that this was due to the fact that the research population was only at ICH and thus in a geographical area which was less affected by SARS-CoV-

2. Indeed, when we compared the frequencies of research and staff personnel only at ICH, we found an opposite trend (Fig. 3D).

We then evaluated whether there was a correlation between the number and typology of self-reported symptoms and the frequency of antibody response both as number of individuals (Fig. 4A, B) and as percentage on the whole population (Fig. 4C, D). As shown in Fig. 4 when analyzing individuals deemed to be positive on the basis of the amount of IgG (>12 AU/mL) we observed a two phases decay: first a similar frequency (A) or number (C) of subjects with 0 to 7 concomitant symptoms, and then a drop of individuals at higher number of concomitant symptoms. This distribution followed a sigmoidal, four parameter logistic curve whereby X is the number of symptoms (R^2=0.97). By contrast, in the population with IgG <12 AU/mL we found a higher number (B) or frequency (D) of individuals with 0, 1 or 2 symptoms and the distribution was following an exponential curve (R^2=0,9975) (Fig. 4B, D). The multivariate analysis showed that, among the symptoms, fever, anosmia/ageusia (loss of smell or taste) and breath difficulties/dyspnea were those that best characterized the IgG positive population, particularly when collated. Indeed, dividing the population according to the number of symptoms, IgG positivity increased from 5% in the absence of symptoms to 41% in the presence of 5 symptoms or more (Table 3), and the value of the AUC was 79%, while the combination of just fever versus anosmia/ageusia (loss of taste and sense of smell) had an AUC of 78%. 81% of individuals presenting both anosmia/ageusia and fever resulted SARS-CoV-2 infected. These results indicate that there are symptoms that best characterize the paucisymptomatic COVID-19 population and that when individuals present with fever and anosmia they are likely to have SARS-CoV-2 infection.

When we analyzed if there was any correlation between IgG positivity and comorbidities, we could not detect any correlation (Table 4). The same was true for the number or type of vaccination (Flu, pneumococcus, tuberculosis) versus IgG positive individuals (Table 5).

We also assessed which was the major cause of infection according to the self-reported questionnaire. IgG positivity correlated most with family contacts (31.2%, *p=0.0001*), suggesting that this was the major cause of infection (Table 6).

IgG plasma levels and population characteristics

The frequency of IgG positive individuals clearly reflected the increased exposure to the virus across the analyzed geographical areas, correlated with COVID-related symptoms and showed a higher proportion of positivity within females. However, one advantage of using a quantitative assay for IgG testing allows to assess also the magnitude of the immune response. Hence, we analyzed the data also in relation to IgG plasma levels. First, we assessed whether the level of plasma IgG correlated with positivity to the nasal swab. We found that there was no correlation between nasal swab positivity and IgG plasma levels (Fig. 5A). To take into account a possible temporal confounding

factor of symptoms detection and serological test, we compared the IgG plasma levels of swab positive individuals with that of the ascertained COVID-19 population (between the months of March and April) within this cohort. We could not detect any statistically significant difference between IgG >12 nasal swab positive and the COVID-19 populations, suggesting that the positivity to the swab does not correlate with a higher IgG plasma level (Fig. 5A). Consistently, we could not detect statistically significant difference in IgG plasma levels in the IgG>12 AU/mL population divided by nasal swab negative and positive, even though the latter seemed slightly higher (Fig. 5A).
When we analyzed the plasma level of IgG in individuals coming from the different sites, we did not detect any statistically significant difference (Fig. 5B). This indicates that while the proportion of individuals exposed to the virus was higher in the Bergamo area (Gavazzeni and Castelli), the magnitude of the response was similar (Suppl. Table 2). We observed a difference in the proportion of IgG positive individuals between males and females. This may indicate either a higher exposure to the virus, a higher incidence of infection or a higher ability to mount an immune response. Thus, we evaluated whether this difference was paralleled by increased IgG plasma levels, but there was no difference between IgG plasma levels of males versus females, suggesting a similar magnitude of the immune response (Fig. 5C, Suppl. Table 2). However, when assessing a difference of IgG plasma levels across age ranges, males between 41 and 50 yo had significantly higher plasma levels of IgG than younger individuals (21-30 or 31-40) (Fig. 5D). This, together with the finding that middle-aged men had also a higher frequency of IgG positive individuals, suggests that they seem to respond better in terms of antibody production (Fig. 5D). This is in line with a recent report in COVID-19 patients showing that younger patients developed lower titers of IgG [10]. The difference of IgG response between females and males in relation to age remains quite intriguing and we still have to understand its relevance with the higher incidence of COVID-19 in males [9]. Interestingly, while smoking seemed to inversely correlate with the frequency of IgG positive individuals, it did not have any effect on IgG plasma levels (Suppl. Fig. 3).

We have shown that the distribution of the IgG positive (>12 AU/mL) population followed a sigmoidal curve with a constant level of individuals up to 7 concomitant symptoms, we thus evaluated whether there was also a correlation between the plasma level of IgG and the number of symptoms. The distribution of IgG levels in the population versus the cumulative symptoms was very similar when analyzing the whole population or those of ICH and Gavazzeni which had different proportions of IgG positive individuals (Suppl. Fig. 4). They were characterized by similar areas under the curve (All: 571; ICH: 550; Gavazzeni: 522) and the respective Receiver Operating Characteristics (ROC) curves were perfect (100%) confirming maximal specificity and sensitivity of the IgG test at IgG >12 AU/mL (Suppl. Fig. 4). We observed a direct correlation between the number of concomitant symptoms and an increase in the level of plasma

IgG (Fig. 6A, Suppl. Table 3; *p<0.0001*). By contrast, the level of IgG in the population < 12 AU/mL was constant, regardless of the number of symptoms (Fig. 6B). Individuals with pneumonia had significantly higher levels of IgG than individuals with any other symptom (Fig. 6C). Further, when we analyzed the levels of IgG in those individuals displaying fever, anosmia/ageusia or dyspnea, or fever and anosmia/ageusia alone, they were all higher than those of subjects with 0 symptoms, when considering the whole spectrum of IgG (also those between 3.8 and 12 AU/mL) (Fig. 6D, Suppl. Table 3, *p<0.0001*). This confirms that these symptoms are the ones best characterizing SARS-CoV-2 infection. No statistically significant differences in IgG plasma levels were observed in relation to comorbidities (Suppl. Table 4) or vaccinations (Suppl. Table 5).

When analyzing IgG plasma levels across different professional groups we did not observe any statistically significant difference, but a tendency to higher IgG levels in healthcare physicians and nurses (Suppl. Fig. 5).

Discussion

Our study is the first report of a comprehensive analysis of nearly 4000 individuals from different sanitary structures representative of dramatically different levels of SARS-CoV-2 exposure in Lombardy, the most affected region by COVID-19 in Italy. We observed a range of positivity which strongly correlated with the geographical area of viral exposure from 3% in the Varese area to 43% in the Bergamo area, which were respectively the most or less COVID-affected Lombardy provinces. The proportion of IgG positive females was higher than that of males in all of the analyzed hospitals. However, we found a lower proportion of IgG positive individuals in females older than 60 years old than in age-matched males. This is quite intriguing as males and females are equally affected by COVID-19, but males have a worse prognosis [11]. Through the use of a quantitative antibody test of IgG we were also able to assess the magnitude of the immune response. We found that younger males (below 40 yo) displayed reduced IgG plasma levels than older males (from 41 yo onwards). This is in line with a recent report in COVID-19 patients showing that younger patients developed lower titers of IgG [10]. Thus, also in the healthy population, younger males exposed to the virus develop a reduced antibody response. Hence, it is very important when analyzing the serology to SARS-CoV-2 to take into account both age and sex.

Our study differs from the one reported by Sood and colleagues in Los Angeles County[12] as we used a quantitative antibody test and analyzed a large hospital population which ranged from healthcare professionals, researchers and administrative staff. Indirectly, we show that it is rather the environment than the hospital professional exposure which dictates the probability of contracting SARS-CoV-2 infection. Indeed, we show a higher percentage of IgG positive individuals among

those who had been in contact with COVID-19 affected relatives and a similar proportion of IgG positive individuals among healthcare professionals and administrative staff which worked from home. However, the magnitude of the antibody response in terms of plasma levels of IgG, even though not statistically significant, was higher in healthcare professionals suggesting that these individuals developed a more sustained immune response. We were also able to pinpoint 10% of IgG positive individuals which were completely asymptomatic and another 20% of paucisymptomatic subjects with 1 or 2 symptoms. When considering the whole population of asymptomatics, the percentage of IgG positive individuals was 5%. This indicates that a good proportion of individuals are infected without even knowing it. These subjects may be the ones that most likely transmit the infection. Among the symptoms, those that characterized most the IgG positive population were fever and anosmia/ageusia. 81% of individuals presenting both anosmia/ageusia and fever resulted SARS-CoV-2 infected, indicating that these symptoms are strongly associated to COVID-19.

Selected vaccines such as BCG have been suggested to increase pathogen-agnostic off-target resistance to infectious agents [13]. However, a recent report showed no differences in incidence of COVID-19 in BCG vaccinated versus non vaccinated patient population [14]. In line with this, we did not observe a correlation between IgG positivity and vaccination.

Intriguingly, We observed an inverse correlation between induction of an antibody response and smoking habit. This may indicate either a lower incidence of SARS-CoV-2 infection in smokers, or their inability to induce an immune response to the virus. The interpretation of this result remains to be understood as the role of smoking in COVID-19 infection is still controversial, as stated by the WHO (https://www.who.int/news-room/detail/11-05-2020-who-statement-tobacco-use-and-COVID-19).

In conclusion, we show that antibody testing can identify the population that was exposed to SARS-CoV-2 and is a powerful tool to retrospectively evaluate viral diffusion, even in asymptomatic individuals. Our study is ongoing and will allow us to assess the evolution of the IgG response over a planned follow up of one year and more. Should a second wave of SARS-CoV-2 infection occur, the wide range of IgG serology in the different sites will be particularly valuable as it will allow us to assess the role of antibodies in viral protection and whether there is a long lasting immunity. The results presented here suggest that hospital health care professionals, staff and researchers can provide invaluable information to assess variables affecting the immune response to SARS-CoV-2 as a snapshot and during the follow-up

Acknoweledgments

We would like to thank all the employees that volunteered to participate to this study, all the nurses and personnel that collected the samples and the laboratory technicians that run the serological and rinopharyngeal tests. We would also like to thank the Humanitas management and staff, Drs Patrizia Meroni and Michele Tedeschi, who warmly supported this study for the safety of the employees. Dr Alice Bertocchi for critical reading of the manuscript. This work was partially supported by a phylantropic donation by Dolce & Gabbana and by the Italian Ministry of Health (Ricerca corrente)

References

1. Wang, W.*, et al.* Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *JAMA* (2020).
2. Lippi, G., Simundic, A.M. & Plebani, M. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). *Clin Chem Lab Med* (2020).
3. Long, Q.X.*, et al.* Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat Med* (2020).
4. Xiang, F.*, et al.* Antibody Detection and Dynamic Characteristics in Patients with COVID-19. *Clin Infect Dis* (2020).
5. Huan Ma, W.Z., Hongliang He, Dan Zhao, Yunru Yang, Dehua Jiang, Peigen Yingjie, Weihuang He, Changcheng Zhao, Ruting Yi, Xiaofang Wang, Bo Wang, Yuanhong Yun Yang, Arnaud John Kombe Kombe, Chengchao Ding, Jiajia Xie, Yong Gao, Linzhao Cheng1, Yajuan Li, Xiaoling Ma, Tengchuan Jin. COVID-19 diagnosis and study of serum 1 SARS-CoV-2 specific IgA, IgM and IgG by chemiluminescence immunoanalysis. *MedRXiv* (2020).
6. Wolfel, R.*, et al.* Virological assessment of hospitalized patients with COVID-2019. *Nature* (2020).
7. B, L. Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset.
8. Zhao, J.*, et al.* Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. *Clin Infect Dis* (2020).
9. Wu, Z. & McGoogan, J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA* (2020).
10. Wu, F.W., A, Liu, M. Wang, O, Chen, J, ..Jinghe Huang. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. *MedXriv* (2020).
11. Jin, J.M.*, et al.* Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. *Front Public Health* **8**, 152 (2020).
12. Sood, N.*, et al.* Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020. *JAMA* (2020).

13. Netea, M.G., *et al.* Defining trained immunity and its role in health and disease. *Nat Rev Immunol* (2020).
14. Hamiel, U., Kozer, E. & Youngster, I. SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults. *JAMA* (2020).

Figure legends

Figure 1. Distribution of IgG positivity (>12 AU/mL) across different geographical areas and hospitals in Lombardy, Italy.

Employees from 7 different sites were analyzed for their anti-SARS-CoV-2 IgG positivity in peripheral blood. Results are shown in percentages as parts of a whole plots across all the different sites (All) or by individual site Istituto Clinico Humanitas (ICH), Rozzano, Mi; Humanitas Gavazzeni, Bergamo; Humanitas Castelli, Bergamo; Humanitas Mater Domini (HMD), Castellanza (Va); Humanitas Medical Center, HMC, Varese, Mi; Humanitas University, Pieve Emanuele (Mi); Humanitas San Pio X, Milano. In orange, the percentage of negative subjects (IgG <12 AU/mL) and in blue, that of positive subjects (IgG >12 AU/mL).

Figure 2. Distribution of IgG positivity (>12 AU/mL) between males and females by site.

The percentage of the population of females versus males is reported for the major sites (Milan (whole institute in Milan), Gavazzeni and Castelli). Upper plots: females, lower plots: males. In orange, the percentage of negative subjects (IgG <12 AU/mL) and in blue, that of positive subjects (IgG >12 AU/mL).

Figure 3. Frequency of IgG positivity (IgG > 12 AU(mL) by age and professional status.

Histograms show: A. the number of positive individuals (IgG > 12 AU/mL) divided by age range and sex. B. the percentage of positive individuals (IgG > 12 AU/mL) divided by age range and sex C. the percentage of positive individuals (IgG > 12 AU/mL) divided by professional status healthcare physicians, healthcare non-physicians (instrument technicians), administrative staff, research personnel, nurses (OSA), and customer service (check-in, admissions) as average of the different sites. D. the percentage of positive individuals (IgG > 12 AU/mL) in ICH only as administrative staff and research personnel. **** $p<0.0001$; n. s. not significant as calculated by the multivariate analysis of Table 1.

Figure 4. Distribution of the IgG >12 and IgG<12 populations versus the number of symptoms

A, C. Distribution of the IgG positive individuals (IgG > 12 AU/mL) as number of individuals (A) or percentage of the population (C) versus the number of self-reported symptoms. The curve that best interpolated the data was a individuals (IgG > 12 AU/mL) was a sigmoidal, four parameter logistic curve whereby X is the number of symptoms (R^2=0.97). B, D. . Distribution of the IgG negative individuals (IgG < 12 AU/mL) as number of individuals (B) or percentage of the

population (D) versus the number of self-reported symptoms. The curve that best interpolated the data was exponential (R^2=0,9975).

Figure 5. Distribution of IgG plasma levels in the different populations.

A,. Distribution of IgG plasma levels in the cohort of IgG positive individuals (IgG > 12 AU/mL) divided by: negativity to the rinopharyngeal (nasal) swab, positivity to the nasal swab, or ascertained COVID-19 disease. B. Distribution of IgG plasma levels in IgG positive individuals (IgG > 12 AU/mL) divided by site. C. Distribution of IgG plasma levels in IgG positive individuals (IgG > 12 AU/mL) divided by sex. C. Distribution of IgG plasma levels in IgG positive individuals (IgG > 12 AU/mL) divided by age ranges. n.s. not significant, * p< 0.05, as calculated by ordinary one-way ANOVA multiple comparisons column by column.

Figure 6. Distribution of IgG plasma levels in relation to symptoms

A,. Distribution of IgG plasma levels versus the number of self-reported symptoms in IgG positive individuals (IgG > 12 AU/mL). B. Distribution of IgG plasma levels versus the number of self-reported symptoms in IgG negative individuals (IgG < 12 AU/mL). C. Distribution of IgG plasma levels versus each individual symptom in IgG positive individuals (IgG > 12 AU/mL). C. Distribution of IgG plasma levels versus selected symptoms (Fever, Anosmia/Ageusia or shorth.breath/dyspnea in individuals with(IgG above the detection limit (IgG> 3.8 AU/mL). *** p< 0.001; **** p< 0.0001 as calculated by ordinary one-way ANOVA multiple comparisons column by column.

Materials and Methods

Clinical Study

The study has been approved by the international review board of Istituto Clinico Humanitas for all participating institutes (clinicaltrial.gov NCT04387929). Accrual was on a voluntary basis: it started on April 28th and more than 65% of employees participated as of May 16th, 2020. 7 different centers participated to the study: Istituto Clinico Humanitas (ICH), Rozzano, Mi; Humanitas Gavazzeni, Bergamo; Humanitas Castelli, Bergamo; Humanitas Mater Domini (HMD), Castellanza (Va); Humanitas Medical Center, HMC, Varese, Mi; Humanitas University, Pieve Emanuele (Mi); Humanitas San Pio X, Milano. All participants signed an informed consent and filled an anamnestic questionnaire before blood collection. All subjects with IgG > 12 AU/mL underwent a rinopharungeal swab for SARS-CoV-2 viral RNA detection.

SARS-CoV-2 RT-PCR

Rinopharyngeal swab were tested with a commercial RT-PCR assay (AllplexTM2019-nCoV Assay – Seegene, Seoul, South Korea), according to manufacturer's instruction. RNA extraction was performed using Seegene Nimbus, a liquid handler workstation, Real-time PCR was run on a CFX96 TMDx thermocycler (Bio-Rad Laboratories, Inc, CA, USA) and subsequently interpreted by Seegene's Viewer software. The test target three viral genes (*E, RdRp* and *N*).

IgG determination

For the determination of IgG anti SARS-CoV-2 the Liaison SARS-CoV-2 S1/S2 IgG assay (DiaSorin, Saluggia (VC), Italy) was used. The method is an indirect chemiluminescence immunoassay for the determination of anti-S1 and anti-S2 specific antibodies. Intra- and inter-assay coefficient of variation are <1.9% and <3.7% respectively.

Statistics

A multivariate logistic model was used to analyze the data. The model was chosen for its capacity of being the most explicative one on the basis of the AIC statistics and the x2 residual to explain the variability. The 4 model variable is the one that gave the lowest AIC.

Prism 8 Graphpad has been used for all the statistics associated to the figures. One way ANOVA has been used for multiple comparisons and Student's t test for one to one comparisons.

A Distribution of IgG positivity



B



Fig. 1 Distribution of IgG >12 AU/mL individuals according to sites



Fig. 2 Distribution of IgG >12 AU/mL Females Vs Males according to sites



Fig. 3 IgG positivity by Age and professional status



Fig. 4 Distribution of the IgG >12 and IgG<12 populations versus the number of symptoms.



Fig. 5 IgG plasma levels in the different populations



Fig. 6 IgG plasma levels in relation to symptoms

Table 1 Characteristics of the population in relation to IgG positivity

	Total		Serology							
			Negative (<12AU/mL)		Equivocal (12÷15AU/mL)		Positive (>15AU/mL)		Dositive (>12AU/mL)	
	N	% of total	N	%	N	%	N	%	N	%
Age> 60 yo										
No	3698	92.8	3200	86.5	75	2.0	423	11.4	498	13.5
Si	287	7.2	262	91.3	1	0.3	24	8.4	25	8.7
Males										
No	2660	66.8	2288	86.0	57	2.1	315	11.8	372	14.0
Si	1325	33.2	1174	88.6	19	1.4	132	10.0	151	11.4
BMI										
.	318	8.0	282	88.7	4	1.3	32	10.1	36	11.3
BMI lt 20	432	10.8	368	85.2	12	2.8	52	12.0	64	14.8
BMI lt 25	1947	48.9	1695	87.1	41	2.1	211	10.8	252	12.9
BMI lt 30	1004	25.2	876	87.3	14	1.4	114	11.4	128	12.7
BMI lt 35	219	5.5	185	84.5	5	2.3	29	13.2	34	15.5
BMI ge 35	65	1.6	56	86.2	.	.	9	13.8	9	13.8
number of smoked cigarettes										
.	2	0.1	2	100.0	.	.	.	.	.	.
0 cigarette/die	3032	76.1	2580	85.1	66	2.2	386	12.7	452	14.9
1-10 cigarette/die	731	18.3	666	91.1	10	1.4	55	7.5	65	8.9
11-20 cigarette/die	214	5.4	208	97.2	.	.	6	2.8	6	2.8
21 or more cigarette/die	6	0.2	6	100.0	.	.	.	.	.	.
Working sites										
Humanitas ICH	2558	64.2	2329	91.0	38	1.5	191	7.5	229	9.0
Humanitas University	64	1.6	59	92.2	1	1.6	4	6.3	5	7.8
Humanitas Medical Care	67	1.7	65	97.0	.	.	2	3.0	2	3.0
Humanitas San Pio X	250	6.3	234	93.6	3	1.2	13	5.2	16	6.4
Humanitas Mater Domini	341	8.6	328	96.2	1	0.3	12	3.5	13	3.8
Humanitas Castelli	133	3.3	76	57.1	4	3.0	53	39.8	57	42.9
Humanitas Gavazzeni	572	14.4	371	64.9	29	5.1	172	30.1	201	35.1

	Total		Serology							
			Negative (<12AU/mL)		Equivocal (12÷15AU/mL)		Positive (>15AU/mL)		Dositive (>12AU/mL)	
	N	% of total	N	%	N	%	N	%	N	%
Humanitas Milano	3280	82.3	3015	91.9	43	1.3	222	6.8	265	8.1
Professional status										
Physician	659	16.5	569	86.3	22	3.3	68	10.3	90	13.7
Surgeon	287	7.2	245	85.4	3	1.0	39	13.6	42	14.6
Anesthesiologist	112	2.8	104	92.9	4	3.6	4	3.6	8	7.1
Physioterapist	72	1.8	60	83.3	6	8.3	6	8.3	12	16.7
Nurse	1014	25.4	859	84.7	18	1.8	137	13.5	155	15.3
Research	123	3.1	109	88.6	4	3.3	10	8.1	14	11.4
Laboratory technician	50	1.3	47	94.0	1	2.0	2	4.0	3	6.0
Student	28	0.7	25	89.3	1	3.6	2	7.1	3	10.7
Instruments technician	173	4.3	156	90.2	.	.	17	9.8	17	9.8
Other	1467	36.8	1288	87.8	17	1.2	162	11.0	179	12.2
Total	3985	100.0	3462	86.9	76	1.9	447	11.2	523	13.1

Table 2. Nasal swab positivity in relation to IgG positivity

	Total		Nasal swab positivity							
			Negative		Positive low load		Positive		Positive	
	N	% of total	N	%	N	%	N	%	N	%
Serology										
Negative (<12AU/mL)	46	8.2	46	100.0	.	.	.	.	.	.
Equivocal (12÷15AU/mL)	75	13.3	70	93.3	3	4.0	2	2.7	5	6.7
Positive (>15AU/mL)	441	78.5	407	92.3	28	6.3	6	1.4	34	7.7
Positive (>12AU/mL)	516	91.8	477	92.4	31	6.0	8	1.6	39	7.6
Total	562	100.0	523	93.1	31	5.5	8	1.4	39	6.9

Table 3. Association of symptoms with IgG positivity

	Total		Serology							
			Negative (<12AU/mL)		Equivocal (12÷15AU/mL)		Positive (>15AU/mL)		Positive (>12AU/mL)	
	N	% of total	N	%	N	%	N	%	N	%
Fever										
No	3488	87.5	3179	91.1	56	1.6	253	7.3	309	8.9
Yes	497	12.5	283	56.9	20	4.0	194	39.0	214	43.1
Fever-like										
No	3557	89.3	3149	88.5	63	1.8	345	9.7	408	11.5
Yes	428	10.7	313	73.1	13	3.0	102	23.8	115	26.9
Cough										
No	3074	77.1	2750	89.5	57	1.9	267	8.7	324	10.5
Yes	911	22.9	712	78.2	19	2.1	180	19.8	199	21.8
Sorethroat – runny nose										
No	2687	67.4	2391	89.0	50	1.9	246	9.2	296	11.0
Yes	1298	32.6	1071	82.5	26	2.0	201	15.5	227	17.5
Muscular pain										
No	2957	74.2	2707	91.5	42	1.4	208	7.0	250	8.5
Yes	1028	25.8	755	73.4	34	3.3	239	23.2	273	26.6
Asteenia										
No	3237	81.2	2948	91.1	43	1.3	246	7.6	289	8.9
Yes	748	18.8	514	68.7	33	4.4	201	26.9	234	31.3
Anosmia, Ageusia										
No	3617	90.8	3348	92.6	46	1.3	223	6.2	269	7.4
Yes	368	9.2	114	31.0	30	8.2	224	60.9	254	69.0
Gastrointestinal symtoms										
No	3165	79.4	2812	88.8	52	1.6	301	9.5	353	11.2
Yes	820	20.6	650	79.3	24	2.9	146	17.8	170	20.7
Conjunctivitis										
No	3583	89.9	3145	87.8	64	1.8	374	10.4	438	12.2
Yes	402	10.1	317	78.9	12	3.0	73	18.2	85	21.1
Dyspnea – breathing difficulties										
No	3726	93.5	3291	88.3	67	1.8	368	9.9	435	11.7

	Total		Serology							
			Negative (<12AU/mL)		Equivocal (12÷15AU/mL)		Positive (>15AU/mL)		Positive (>12AU/mL)	
	N	% of total	N	%	N	%	N	%	N	%
Yes	259	6.5	171	66.0	9	3.5	79	30.5	88	34.0
Chest pain										
No	3664	91.9	3235	88.3	62	1.7	367	10.0	429	11.7
Yes	321	8.1	227	70.7	14	4.4	80	24.9	94	29.3
Tachicardia										
No	3553	89.2	3112	87.6	62	1.7	379	10.7	441	12.4
Yes	432	10.8	350	81.0	14	3.2	68	15.7	82	19.0
Pneumonia										
No	3951	99.1	3457	87.5	75	1.9	419	10.6	494	12.5
Yes	34	0.9	5	14.7	1	2.9	28	82.4	29	85.3
Others										
No	3828	96.1	3341	87.3	71	1.9	416	10.9	487	12.7
Yes	157	3.9	121	77.1	5	3.2	31	19.7	36	22.9
Number of symptoms										
0 symptoms	1380	34.6	1318	95.5	11	0.8	51	3.7	62	4.5
1 symptoms	814	20.4	758	93.1	10	1.2	46	5.7	56	6.9
2 symptoms	582	14.6	517	88.8	11	1.9	54	9.3	65	11.2
3 symptoms	411	10.3	350	85.2	10	2.4	51	12.4	61	14.8
4 symptoms	256	6.4	201	78.5	8	3.1	47	18.4	55	21.5
5 or more symptoms	542	13.6	318	58.7	26	4.8	198	36.5	224	41.3
Fever e disgeusia	3285	82.4	3096	94.2	39	1.2	150	4.6	189	5.8
No										
Fever	203	5.1	83	40.9	17	8.4	103	50.7	120	59.1
Anosmia/Disgeusia	332	8.3	252	75.9	7	2.1	73	22.0	80	24.1
Fever and Anosmia/Disgeusia	165	4.1	31	18.8	13	7.9	121	73.3	134	81.2
Total	3985	100.0	3462	86.9	76	1.9	447	11.2	523	13.1

Table 4. Correlation between comorbidities and IgG positivity

	Total		Serology							
			A Negative (<12AU/mL)		A Negative (<12AU/mL)		A Negative (<12AU/mL)		A Negative (<12AU/mL)	
	N	% of total	N	%	N	%	N	%	N	%
Chronic obstructive pulmonary disease										
No	3973	99.6	3453	86.9	76	1.9	444	11.2	520	13.1
Yes	17	0.4	14	82.4	.	.	3	17.6	3	17.6
Asthma										
No	3746	93.9	3254	86.9	72	1.9	420	11.2	492	13.1
Yes	244	6.1	213	87.3	4	1.6	27	11.1	31	12.7
Dislipidemia										
No	3623	90.8	3142	86.7	70	1.9	411	11.3	481	13.3
Yes	367	9.2	325	88.6	6	1.6	36	9.8	42	11.4
Current Neoplasia										
No	3986	99.9	3463	86.9	76	1.9	447	11.2	523	13.1
Yes	4	0.1	4	100.0	.	.	.	.	.	.
History of Neoplasia										
No	3879	97.2	3370	86.9	73	1.9	436	11.2	509	13.1
Yes	111	2.8	97	87.4	3	2.7	11	9.9	14	12.6
Chronic cardiac failure										
No	3987	99.9	3464	86.9	76	1.9	447	11.2	523	13.1
Yes	3	0.1	3	100.0	.	.	.	.	.	.
Hypertension										
No	3642	91.3	3164	86.9	71	1.9	407	11.2	478	13.1
Yes	348	8.7	303	87.1	5	1.4	40	11.5	45	12.9
History of Coronaropathy										
No	3965	99.4	3443	86.8	76	1.9	446	11.2	522	13.2
Yes	25	0.6	24	96.0	.	.	1	4.0	1	4.0
Atrial fibrillation										
No	3961	99.3	3443	86.9	76	1.9	442	11.2	518	13.1
Si	29	0.7	24	82.8	.	.	5	17.2	5	17.2
History of stroke										
No	3978	99.7	3456	86.9	76	1.9	446	11.2	522	13.1

	Total		Serology							
			A Negative (<12AU/mL)		A Negative (<12AU/mL)		A Negative (<12AU/mL)		A Negative (<12AU/mL)	
	N	% of total	N	%	N	%	N	%	N	%
Yes	12	0.3	11	91.7	.	.	1	8.3	1	8.3
Steatosis/Cirrhosis										
No	3973	99.6	3452	86.9	74	1.9	447	11.3	521	13.1
Yes	17	0.4	15	88.2	2	11.8	.	.	2	11.8
Other hepatic disorders										
No	3967	99.4	3447	86.9	75	1.9	445	11.2	520	13.1
Yes	23	0.6	20	87.0	1	4.3	2	8.7	3	13.0
Chronic kidney failure										
No	3982	99.8	3460	86.9	76	1.9	446	11.2	522	13.1
Yes	8	0.2	7	87.5	.	.	1	12.5	1	12.5
Rheumatoid arthritis										
No	3926	98.4	3415	87.0	72	1.8	439	11.2	511	13.0
Yes	64	1.6	52	81.3	4	6.3	8	12.5	12	18.8
Other immune disorders										
No	3731	93.5	3247	87.0	73	2.0	411	11.0	484	13.0
Yes	259	6.5	220	84.9	3	1.2	36	13.9	39	15.1
Diabetes mellitus										
No	3948	98.9	3426	86.8	76	1.9	446	11.3	522	13.2
Yes	42	1.1	41	97.6	.	.	1	2.4	1	2.4
Gout										
No	3985	99.9	3462	86.9	76	1.9	447	11.2	523	13.1
Yes	5	0.1	5	100.0	.	.	.	.	.	.
Other Comorbidities										
No	3588	89.9	3105	86.5	72	2.0	411	11.5	483	13.5
Yes	402	10.1	362	90.0	4	1.0	36	9.0	40	10.0
number of comorbidities										
0 comorbidity	2541	63.7	2195	86.4	51	2.0	295	11.6	346	13.6
1 comorbidity	1063	26.6	930	87.5	18	1.7	115	10.8	133	12.5
2 comorbidities	274	6.9	245	89.4	7	2.6	22	8.0	29	10.6
3 comorbidities	82	2.1	71	86.6	.	.	11	13.4	11	13.4

	Total		Serology							
			A Negative (<12AU/mL)		A Negative (<12AU/mL)		A Negative (<12AU/mL)		A Negative (<12AU/mL)	
	N	% of total	N	%	N	%	N	%	N	%
4 or more comorbidities	30	0.8	26	86.7	.	.	4	13.3	4	13.3
Total	3990	100.0	3467	86.9	76	1.9	447	11.2	523	13.1

Table 5. Correlation between IgG positivity and vaccinations

	Total		Serology							
			Negative (<12AU/mL)		Equivocal (12÷15AU/mL)		Positive (>15AU/mL)		Positive (>12AU/mL)	
	N	% of total	N	%	N	%	N	%	N	%
2019/2020 Flu vaccine										
No	2776	69.6	2416	87.0	47	1.7	313	11.3	360	13.0
Si	1214	30.4	1051	86.6	29	2.4	134	11.0	163	13.4
Antipneumococcus										
No	3856	96.6	3356	87.0	68	1.8	432	11.2	500	13.0
Si	134	3.4	111	82.8	8	6.0	15	11.2	23	17.2
Anti-Tubercolar										
No	3603	90.3	3126	86.8	66	1.8	411	11.4	477	13.2
Si	387	9.7	341	88.1	10	2.6	36	9.3	46	11.9
Other Vaccinations										
No	3707	92.9	3218	86.8	71	1.9	418	11.3	489	13.2
Si	283	7.1	249	88.0	5	1.8	29	10.2	34	12.0
number of vaccinations										
0 vaccination	2305	57.8	2002	86.9	37	1.6	266	11.5	303	13.1
1 vaccination	1406	35.2	1226	87.2	27	1.9	153	10.9	180	12.8
2 vaccinations	231	5.8	197	85.3	11	4.8	23	10.0	34	14.7
3 or more vaccinations	48	1.2	42	87.5	1	2.1	5	10.4	6	12.5
Total	3990	100.0	3467	86.9	76	1.9	447	11.2	523	13.1

Table 6. Correlation between IgG positivity and exposure to COVID+ individuals

	Total		Serology							
			Negative (<12AU/mL)		Equivocal (12÷15AU/mL)		Positive (>15AU/mL)		Positive (>12AU/mL)	
	N	% of total	N	%	N	%	N	%	N	%
Contacts										
None	1074	27.0	1011	94.1	11	1.0	52	4.8	63	5.9
Colleague	854	21.5	741	86.8	20	2.3	93	10.9	113	13.2
Patient	1601	40.3	1348	84.2	31	1.9	222	13.9	253	15.8
Family	138	3.5	95	68.8	7	5.1	36	26.1	43	31.2
Other	310	7.8	262	84.5	7	2.3	41	13.2	48	15.5
Total	3977	100.0	3457	86.9	76	1.9	444	11.2	520	13.1